Cidara Therapeutics Earning Date (CDTX)

USA |NASDAQ |USD

CDTX Earnings Date

|
Report Date Period Ending EPS Forecast Last Quarter's EPS Last Year's EPS
Aug 10, 2022 Jun 2022 - - $0.18
Report Date Period Ending Revenue Forecast Last Quarter’s Revenue Last Year’s Revenue
Aug 10, 2022 Jun 2022 - - $32.86M

Cidara Therapeutics's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 2022.

CDTX Earnings Date & History Chart

CDTX Earnings & Revenue Forecast

CDTX Earnings Forecast

|
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $-1.36 $-1.69 $-1.01

CDTX Earnings Revision Trend

|
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Period End Up/Down 1M 1M Trend 2M Trend 3M Trend
Dec 2022 1 / 1 $-1.41 $-1.43 $-1.63

CDTX Revenue Forecast

|
Period End # of Analysts Revenue Forecast Low Revenue Forecast High Revenue Forecast
Period End # of Analysts EPS Forecast Low EPS Forecast High EPS Forecast
Dec 2022 6 $6.38M $0.00 $11.86M

CDTX Earnings Date & Revenue History

CDTX Earnings History

|
Show More
Show More

CDTX Revenue History

|
Show More
Show More

Cidara Therapeutics Next Earnings Date & Report

CDTX Next Earnings Date & Report Preview: Jun 2022 (FQ)

CDTX's next earnings date is Wednesday, Aug 10, 2022 for the fiscal quarter ending Jun 30, 2022.

Cidara Therapeutics Previous Earnings Dates & Reports

CDTX Previous Earnings Date & Report Recap: Mar 2022 (FQ)

Cidara Therapeutics's previous earnings date was May 11, 2022 for its fiscal quarter ended Mar 31, 2022.

CDTX Previous Earnings Date & Report Recap: Dec 2021 (FY)

Cidara Therapeutics's previous annual earnings date was Mar 7, 2022 for its fiscal year ended Dec 31, 2021.

CDTX's earnings per share (EPS) was $-0.84, beating the consensus analysts forecast of $-0.90 by -6.67% , and higher than the previous year's EPS (Dec 2020) by -53.33%.

Revenues were $49.57M, better than the forecast of $43.76M by 13.28%, and up by 310.81% from previous year's revenue.

The company reported a net income of $-42.47M.

Cidara Therapeutics reported a free cash flow of $-25.27M for its fiscal year, compared to $-54.60M a year ago.

The company ended the fiscal year with $5.06M in total debt, a decrease of -36.44% compared to the previous year.